AtriCure fleshes out afib portfolio with Estech buy
This article was originally published in Clinica
AtriCure is bulking up its atrial fibrillation treatment portfolio with the acquisition of surgical ablation specialist Endoscopic Technologies (Estech). The deal, which is expected to close “in the next several weeks”, is worth up to $60m; it consists of an upfront payment of 2.1 million Atricure shares ($34m) and up to $26m of revenue-based milestone payments.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.